Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    July 2024
  1. ISLAM MS, Akter F, Rahman MM, Rafe MR, et al
    Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Jul 16. doi: 10.1007/s00280-024-04700.
    >> Share

  2. MALHI V, Nowicka M, Chen YC, Agarwal P, et al
    UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
    Cancer Chemother Pharmacol. 2024;94:117-122.
    >> Share

    June 2024
  3. MOEIN A, Jin JY, Wright MR, Wong H, et al
    Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic bre
    Cancer Chemother Pharmacol. 2024 Jun 27. doi: 10.1007/s00280-024-04690.
    >> Share

    April 2024
  4. GHORBANI M, Namazi S, Dehghani M, Razi F, et al
    Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Apr 27. doi: 10.1007/s00280-024-04661.
    >> Share

    March 2024
  5. ZHENG W, Peng W, Qian F, Zhang M, et al
    Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-kappaB signaling and reducing NLRP3 expression in triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2024 Mar 8. doi: 10.1007/s00280-024-04660.
    >> Share

  6. YUCEL KB, Aydos U, Sutcuoglu O, Kilic ACK, et al
    Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
    Cancer Chemother Pharmacol. 2024 Mar 4. doi: 10.1007/s00280-024-04641.
    >> Share

  7. MITTRA A, Coyne GHOS, Zlott J, Kummar S, et al
    Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
    Cancer Chemother Pharmacol. 2024;93:177-189.
    >> Share

    February 2024
  8. ELKASAR AO, Hussien FZ, Abdel-Hamied HE, Saleh IG, et al
    Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
    Cancer Chemother Pharmacol. 2024 Feb 7. doi: 10.1007/s00280-023-04620.
    >> Share

    December 2023
  9. XU S, Shi Y, Li S
    Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/beta-catenin signaling pathway in breast cancer.
    Cancer Chemother Pharmacol. 2023 Dec 5. doi: 10.1007/s00280-023-04618.
    >> Share

    September 2023
  10. JABLONSKI M, Rodriguez MS, Rivero EM, Bruque CD, et al
    The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
    Cancer Chemother Pharmacol. 2023 Sep 19. doi: 10.1007/s00280-023-04586.
    >> Share

    August 2023
  11. BEUMER JH, Foldi J
    Pharmacology and pharmacokinetics of elacestrant.
    Cancer Chemother Pharmacol. 2023;92:157-163.
    >> Share

    June 2023
  12. XU G, Yang D, He C, Zhong L, et al
    Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2023 Jun 28. doi: 10.1007/s00280-023-04559.
    >> Share

    May 2023
  13. VARNIER R, Puszkiel A, Tod M, Calattini S, et al
    Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
    Cancer Chemother Pharmacol. 2023;91:361-373.
    >> Share

    March 2023
  14. EL-SADONI M, Shboul SA, Alhesa A, Shahin NA, et al
    A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2023 Mar 24. doi: 10.1007/s00280-023-04523.
    >> Share

    February 2023
  15. LI C, Hao M, Fang Z, Ding J, et al
    PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials.
    Cancer Chemother Pharmacol. 2023 Feb 2. doi: 10.1007/s00280-023-04506.
    >> Share

    January 2023
  16. HJORTH CF, Damkier P, Stage TB, Feddersen S, et al
    The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
    Cancer Chemother Pharmacol. 2023 Jan 4. doi: 10.1007/s00280-022-04499.
    >> Share

    November 2022
  17. XIAO H, Yang X, Huang S
    SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration.
    Cancer Chemother Pharmacol. 2022 Nov 27. doi: 10.1007/s00280-022-04496.
    >> Share

  18. TABUCHI Y, Tsujimoto M, Yamamoto K, Kosaka T, et al
    Incidence and risk factors of infusion reactions in patients with breast cancer administered trastuzumab plus pertuzumab-based regimen.
    Cancer Chemother Pharmacol. 2022 Nov 19. doi: 10.1007/s00280-022-04492.
    >> Share

  19. PROCTOR JR, Gartner EM, Gray TE, Davies RH, et al
    Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
    Cancer Chemother Pharmacol. 2022;90:399-408.
    >> Share

    October 2022
  20. JIAN W, Xue J, Yao Q, Chen R, et al
    Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic-pharmacodynamic model of neutropenia.
    Cancer Chemother Pharmacol. 2022 Oct 22. pii: 10.1007/s00280-022-04484.
    >> Share

  21. SHARAF BM, Giddey AD, Al-Hroub HM, Menon V, et al
    Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab.
    Cancer Chemother Pharmacol. 2022 Oct 20. pii: 10.1007/s00280-022-04478.
    >> Share

    April 2022
  22. MANZO J, Puhalla S, Pahuja S, Ding F, et al
    A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2022 Apr 18. pii: 10.1007/s00280-022-04430.
    >> Share

    February 2022
  23. LIANG Z, Feng A, Shim H
    Retraction Note to: MicroRNA30cregulated HDAC9 mediates chemoresistance of breast cancer.
    Cancer Chemother Pharmacol. 2022 Feb 24. pii: 10.1007/s00280-022-04409.
    >> Share

  24. NICOLETTO RE, Ofner CM 3rd
    Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.
    Cancer Chemother Pharmacol. 2022 Feb 12. pii: 10.1007/s00280-022-04400.
    >> Share

  25. HUANG Y, Yang S, Yu W, Gui L, et al
    Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil.
    Cancer Chemother Pharmacol. 2022 Feb 8. pii: 10.1007/s00280-021-04391.
    >> Share

  26. REDA M, Macaire P, Bellio H, Uwer L, et al
    Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
    Cancer Chemother Pharmacol. 2022;89:197-208.
    >> Share

    January 2022
  27. TAN AR, Chan N, Kiesel BF, Stein MN, et al
    A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
    Cancer Chemother Pharmacol. 2022;89:49-58.
    >> Share

    October 2021
  28. YAO HM, Jones SR, Morales S, Moosavi S, et al
    Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
    Cancer Chemother Pharmacol. 2021 Oct 7. pii: 10.1007/s00280-021-04355.
    >> Share

  29. ROY P, Biswas S, Acharyya S, Dasgupta C, et al
    Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study.
    Cancer Chemother Pharmacol. 2021;88:731-740.
    >> Share

  30. LEENHARDT F, Alexandre M, Guiu S, Pouderoux S, et al
    Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy.
    Cancer Chemother Pharmacol. 2021;88:723-729.
    >> Share

    September 2021
  31. CHEN L, Chen CS, Sun Y, Henry NL, et al
    Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
    Cancer Chemother Pharmacol. 2021;88:475-483.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016